Citations

Clear

5 citation(s) found for "Stewart, Paul A".

TNK1 is a targetable JAK-independent driver of STAT signaling and inflammation
Scott, Samuel, Vaughan, Alec , Egbert, Christina M., Chan, Tsz‐Yin, Bustos, Yaphet , Ashworth, Spencer, Truman, Jacob M., Moreno, Angela Per, Tsang, Tsz‐Ming, Jayatunge, Dasun N., Yang, Jingshu, Nelson, Paige, Al-Sudani, Fatima, Tarara, Madelyn, Kohler, Emmalee, Mendiola, Nelson E. Pereira, Soderblom, Erik J. , Kolasangiani, Reza , Dobish, Kasidy K., Knobel, Beate, Buckley, Shannon M., Bidone, Tamara C., Morawe, Mareen , Armacki, Milena , Andersen, Joshua L., Stewart, Paul A , Smoot, Rory L , López-Palacios, Tania P. , Madhusanka, Deshan , Scott, Samuel M., Egbert, Christina M. , Truman, Jacob, Jayatunge, Dasun , Nelson, Paige, Stubben, Chris , Buckley, Shannon M. , Bidone, Tamara C. , Smoot, Rory L. , Uchida, Amiko M. , Andersen, Joshua L.

Mayo Clinic

Genes & Development | August 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/gad.353368.125 | PMID 42547268 Get It

Deregulated inflammatory signaling via STAT family transcription factors, particularly STAT1, underlies a variety of immune-related diseases, including inflammatory bowel disease. Whereas activation of STATs by JAKs via canonical receptor-driven JAK–STAT signaling is well understood, little is known about JAK-independent mechanisms of STAT activation. Here, we identify the understudied nonreceptor tyrosine kinase TNK1 as a therapeutically targetable, JAK-independent activator of STAT signaling. Using a multiomics approach, we mapped a network of TNK1 substrates associated with protein condensates and proinflammatory signaling, including STAT1. We found that TNK1, but not its sister kinase ACK1, directly phosphorylates STATs at well described STAT-activating JAK sites. In cells, TNK1-mediated STAT1 phosphorylation and activation occurs independently of JAKs. Imaging and interactomics data suggest that TNK1 interacts with STAT1 in cytosolic condensates, which likely compartmentalize TNK1-substrate interactions. We show that an intrinsically disordered proline-rich region in TNK1, which includes a 14-3-3 docking phosphorylation site, is required for the formation of kinase-active TNK1 condensates and STAT1 phosphorylation. Mutations within the proline-rich region that eliminate 14-3-3 binding increase formation of TNK1 condensates, suggesting a model in which 14-3-3 acts as a clamp that constrains the flexible PRR to inhibit condensate formation and STAT1 activation. Finally, we show that TNK1 is a targetable driver of STAT1-mediated inflammation in the gut as inhibition of TNK1 reduces active STAT1 in the colon and ameliorates colitis symptoms in mice.
Consensus on biomarker utility for ACTH-dependent Cushing syndrome: a Pituitary Society Modified Delphi Panel
Fleseriu, Maria , Biller, Beverly M. K. , Reincke, Martín , Мелмед, Шломо , Group, the Pituitary Society International Cushing Syndrome Delphi Panel Consensus, Akirov, Amit , Araki, Takako, Auchus, Richard, Ben-Shlomo, Anat , Bertherat, Jérôme, Biermasz, Nienke R, Castinetti, Frédéric, Ceccato, Filippo, Christ-Crain, Mirjam, Feelders, Richard A. , Findling, James W. , Gadelha, Monica, Geer, Eliza B, Giustina, Andrea, Grossman, Ashley, Gurnell, Mark, Hanzu, Felicia, Hinojosa-Amaya, Jose M, Isand, Kristina , Isidori, Andrea M, Kadioğlu, Pinar, Karavitaki, Niki, McCormack, A I, Nieman, Lynnette, Nowak, Elisabeth, Pivonello, Rosario, Salvatori, Roberto , Stewart, Paul M., Tabarin, Antoine, Takahashi, Yutaka, Theodoropoulou, Marily , Valassi, Elena, Varlamov, Elena V , Walia, Rama, Wass, John, Cheung, Cassandra, Priven, Mariel , Brown, Marielle, Biller, Beverly M K , Bancos, Irina , Fukuoka, Hidenori , Reincke, Martin , Newell-Price, John , Melmed, Shlomo , Bancos, Irina , Newell‐Price, John , Bertherat, Jérôme , Bidlingmaier, Martin , Biermasz, Nienke Ruurdje , Castinetti, Frédéric , Ceccato, Filippo , Christ‐Crain, Mirjam , Gadelha, Mônica R. , Geer, Eliza B. , Glezer, Andréa , Giustina, Andrea , Greenman, Yona , Grossman, Ashley, Gurnell, Mark , Hanzu, Felicia Alexandra , Hinojosa‐Amaya, José Miguel , Isidori, Andrea M. , Kadıoğlu, Pınar , Karavitaki, Niki , Langlois, Fabienne , Nieman, Lynnette K. , Nowak, Elisabeth , Pereira, Alberto M. , Petersenn, Stephan , Pivonello, Rosario , Tabarin, Antoine , Valassi, Elena , Vila, Greisa , Brown, Marielle, Fleseriu, Maria

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | July 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1210/clinem/dgag279 | PMID 42460773 Get It

Abstract Context Biochemical test results are central to clinical decision-making for the diagnosis and management of Cushing syndrome (CS). With emerging research and increasing availability of different tests, updated consensus on the utility of these biomarkers is warranted. Objective To establish an updated consensus on the role of biomarkers in the diagnosis and monitoring of adrenocorticotropic hormone-dependent CS, address novel therapeutic approaches, and identify areas for future research. Design A modified 2-round Delphi panel was conducted. Consensus was defined as ≥70% agreement/disagreement for Likert-scale statements or ≥70% selection of the same option for single-choice questions. Setting Participants represented a range of international expertise. Participants Forty-one participants took part in the Delphi panel, with no attrition between rounds (one nonclinician was not required to complete the second round). An 8-member Steering Committee guided statement development. Results Of statements designed to reach consensus, 45% (14/31) and 44% (11/25) statements reached consensus in Rounds 1 and 2, respectively. Notably, most panelists reported the use of late-night salivary cortisol for diagnosis of mild CS and for monitoring following pituitary surgery or medical or radiation therapy. Most panelists responded that block-and-replace therapies can be considered in patients with cyclical or severe CS, and consensus was reached that restoration of circadian rhythm is a treatment goal for patients with CS. Conclusion Areas of alignment among experts on the diagnosis and monitoring of CS are presented. The findings from this study are intended to support clinicians in their clinical decision-making and highlight priority areas for future research.
Development and Reporting of Prediction Models: Guidance for Authors From Editors of Respiratory, Sleep, and Critical Care Journals
Leisman, Daniel E. , Harhay, Michael O., Adjei, Alex A. , Bakker, Jan , Barreiro, Esther , Bell, Scott C. , Bernstein, Jonathan A. , Branson, Richard D. , Brusasco, Vito , Chalmers, James D. , Chokroverty, Sudhansu , Citerio, Giuseppe , Collop, Nancy A. , Cooke, Colin R. , Crapo, James D. , Donaldson, Gavin C. , Grainger, Emma, Herth, Felix , Marks, Guy B. , Moorman, J. Randall , Ost, David E. , Schätz, Michael , Smyth, Alan R , Stewart, Iain , Stewart, Paul W. , Swenson, Erik R. , Szymusiak, Ronald , Wedzicha, Jadwiga A. , Ost, David E , Bakker, Jan , Marks, Guy B , Chalmers, James D , Harhay, Michael Oscar , Lederer, David J. , Abramson, Michael John , Ballas, Zuhair K. , Bellomo, Rinaldo , Fitzgerald, Dominic A. , Hale, Lauren E. , Kochanek, Patrick Michael , Sheikh, Aziz , Teboul, Jean–Louis , Vincent, Jean‐Louis , Maslove, David M.

Mayo Clinic

Critical Care Medicine | March 6, 2020 | Volume: 48 | Issue: 5 | Pages: 623-633

10.1097/ccm.0000000000004246 | PMID 32141923 Get It

Prediction models aim to use available data to predict a health state or outcome that has not yet been observed. Prediction is primarily relevant to clinical practice, but is also used in research, and administration. While prediction modeling involves estimating the relationship between patient factors and outcomes, it is distinct from casual inference. Prediction modeling thus requires unique considerations for development, validation, and updating. This document represents an effort from editors at 31 respiratory, sleep, and critical care medicine journals to consolidate contemporary best practices and recommendations related to prediction study design, conduct, and reporting. Herein, we address issues commonly encountered in submissions to our various journals. Key topics include considerations for selecting predictor variables, operationalizing variables, dealing with missing data, the importance of appropriate validation, model performance measures and their interpretation, and good reporting practices. Supplemental discussion covers emerging topics such as model fairness, competing risks, pitfalls of “modifiable risk factors”, measurement error, and risk for bias. This guidance is not meant to be overly prescriptive; we acknowledge that every study is different, and no set of rules will fit all cases. Additional best practices can be found in the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) guidelines, to which we refer readers for further details.
The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline
Nieman, Lynnette K. , Findling, James W. , Newell‐Price, John , Savage, Martin O. , Stewart, Paul M. , Montori, Víctor M. , Biller, Beverly M. K. , Montori, Victor M , Newell-Price, John

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | March 11, 2008 | Volume: 93 | Issue: 5 | Pages: 1526-1540

10.1210/jc.2008-0125 | PMID 18334580 Get It